Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #51 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Lincoln Pharmaceuticals Ltd Q3 FY26 key numbers
- Revenue
- New Cephalosporin block factory expected to generate around INR45 crores revenue this year, targeting INR150 crores eventually.
As stated in Lincoln Pharmaceuticals Ltd's Q3 FY26 earnings call transcript · published 26 May 2026. Reported figures, not investment advice.
The short version
Lincoln Pharmaceuticals targets INR1,000 crores revenue by FY 2028, possibly with a 5-6 months delay. Lincoln Pharmaceuticals aims for a revenue growth rate between 15% to 18% for the next year, with potential to exceed 18%.
From Lincoln Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Lincoln Pharmaceuticals targets INR1,000 crores revenue by FY 2028, possibly with a 5-6 months delay.
- Current capacity utilization allows for a 15-20% increase in revenue without new plants.
- New Cephalosporin block factory expected to generate around INR45 crores revenue this year, targeting INR150 crores eventually.
- Growth avenues include organic expansion through new plants, inorganic expansion via acquisitions, and increased registrations.
- Export markets (Africa, Latin America, Southeast Asia) and regulated markets (Canada, others) drive growth.
- Domestic and export revenue mix targeted at approximately 60-40 to 65-35.
- EBITDA margin expected between 15-18%, with possible upside.
2 more points from Lincoln Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Lincoln Pharmaceuticals is exploring both organic and inorganic growth options.
- They are considering setting up a new plant or acquiring through inorganic expansion to exceed current capacity.
- Focus areas for inorganic expansion include tableting and injectable segments with required accreditations.
- They are also investing in product registrations and regulatory approvals across markets like Canada, Latin America, Europe, with an annual budget of INR 5-7 crores for registrations, forming part of R&D and registration expenses.
2 more points from Lincoln Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Lincoln Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
What the Q3 FY26 call signalled
2 of 4 strong
Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹191 Cr, net profit ₹20 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lincoln Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Lincoln Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Lincoln Pharmaceuticals Ltd Q3 FY26 results?
Lincoln Pharmaceuticals targets INR1,000 crores revenue by FY 2028, possibly with a 5-6 months delay. Lincoln Pharmaceuticals aims for a revenue growth rate between 15% to 18% for the next year, with potential to exceed 18%.
What is Lincoln Pharmaceuticals Ltd share price analysis?
Lincoln Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 12.7 with a market cap of ₹1,229 Cr. Investors should review the full earnings analysis for detailed insights.
Is Lincoln Pharmaceuticals Ltd planning capital expenditure?
Lincoln Pharmaceuticals is exploring both organic and inorganic growth options.
Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.